Inven2 are responsible for assessing and commercialising innovative research conducted at the University of Oslo, Oslo University Hospital and the health trusts under the South-Eastern Norway Regional Health Authority.
Since the establishment of Inven2 13 years ago, we have contributed to the establishment of 71 companies and 428licenses alongside innovative researchers. This has led to NOK 773 million being channelled back to research and innovation.
Innovation motivated by patients
Jan Terje Andersen learnt about laboratory work when he was studying to become a biomedical laboratory scientist. Scientific curiosity led him to the Department of Biosciences at the University of Oslo.
A lecture by Professor Inger Sandlie decided his future career. Today, he is one of the researchers with the most innovations at Inven2.
Products on the market
Latest innovation news
Inven2 is grateful to everyone who has contributed to building business and helping patients through new inventions, clarification, clinical...
The Nordic Life Science Days is the largest partnering conference for life sciences in the Nordic countries. Inven2 will participate with a joint...
Licensing validates Norwegian platform technology for the development of tailored monoclonal antibodies
This summer, the U.S.-based biotechnology company Mage Biologics Inc (“Mage Bio”) was formed as a collaboration between the Swiss specialty pharma...